ClinicalTrials.Veeva

Menu

ArcticLine Feasibility Study

M

Medtronic Cardiac Ablation Solutions

Status

Completed

Conditions

Atrial Flutter
Atrial Fibrillation

Treatments

Device: ArcticLine Cardiac Cryoablation Catheter

Study type

Interventional

Funder types

Industry

Identifiers

NCT03604263
MDT16015

Details and patient eligibility

About

The purpose of the ArcticLine Feasibility Study is to collect preliminary safety and effectiveness data on the ArcticLine Catheter.

Enrollment

17 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documentation of symptomatic persistent AF:

    • Defined as having a continuous episode that is sustained beyond 7 days documented via consecutive ECG recordings, or
    • Defined as having a continuous episode that is sustained beyond 7 days documented by an ECG recording and one doctor note indicating the patient had symptoms consistent with AF
  • Age 18 through 80 years old

  • Failure or intolerance of at least one Class I or III antiarrhythmic drug

  • Subject is able and willing to consent to participate in the study and will commit to completion of all follow-up requirements

Exclusion criteria

  • Longstanding persistent AF, defined as continuous AF greater than 12 month duration

  • Left atrial diameter greater than 5.0 cm

  • Active systemic infection

  • History of thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure

  • Prior left atrial ablation attempt, with exception of:

    • Any pulmonary vein isolation attempt to treat AF, or
    • Successful ablation to treat Wolff-Parkinson White syndrome
  • History of left atrial tachycardia

  • History of cardiac ablation within 90 days of planned clinical study procedure

  • Planned concomitant ventricular ablation

  • Cryoglobulinemia

  • Structural heart disease of clinical significance including:

    • NYHA Class IV Heart Failure
    • Diagnosed with NYHA Class III Heart Failure for more than six months at time of the study ablation procedure
    • LVEF less than 35%
    • Any cardiac surgery (e.g. CABG) within 3 months of the ablation procedure
    • Any mechanical heart valve, prior aortic or tricuspid valve replacement (e.g. valvotomy, valve replacement), or tricuspid valve repair
    • Severe mitral valve regurgitation or stenosis
    • Significant congenital anomaly or anatomy unable to accommodate device
  • Prior surgical maze procedure

  • Unstable angina

  • Myocardial infarction within 3 months of the ablation procedure

  • Presence of primum or secundum atrial septal defect

  • Anomalous pulmonary venous return

  • Prior surgery for congenital heart disease, including atrial septal defect repair

  • Hypertrophic cardiomyopathy with LV septal wall thickness >1.5 cm

  • Uncontrolled hyperthyroidism

  • Thrombocytosis, thrombocytopenia (including history of heparin-induced thrombocytopenia)

  • Severe comorbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good study candidate

  • History of blood clotting or bleeding abnormalities

  • Contraindication to all anticoagulation (e.g. novel oral anticoagulants, heparin or warfarin)

  • Pregnant, nursing or planning to become pregnant during study duration

  • Enrollment in another clinical trial without prior approval from Medtronic

  • Presence or use of left atrial appendage closure device

  • Presence of or planned implantation of a pacemaker, implantable cardiac defibrillator, implantable loop recorder or cardiac resynchronization device with permanent lead placement

  • Pre-existing hemidiaphragmatic paralysis

  • Life expectancy less than one year

  • Known drug or alcohol dependency

  • Existing pulmonary vein stent(s)

Trial design

Primary purpose

Device Feasibility

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

17 participants in 1 patient group

Treatment Arm
Experimental group
Description:
Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
Treatment:
Device: ArcticLine Cardiac Cryoablation Catheter

Trial documents
5

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems